Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature

Sandra Guedes1, Isabelle Bertrand-Gerentes1, Keith Evans2, Florence Coste1 and Philipp Oster1*

Abstract

Background: Neisseria meningitidis is an encapsulated Gram-negative diplococcus that asymptomatically colonises the upper respiratory tract in up to 25% of the population (mainly adolescents and young adults). Invasive meningococcal disease (IMD) caused by Neisseria meningitidis imposes a substantial public health burden. The case fatality rate (CFR) of IMD remains high. IMD epidemiology varies markedly by region and over time, and there appears to be a shift in the epidemiology towards older adults. The objective of our review was to assess the published data on the epidemiology of IMD in older adults (those aged ≥ 55 years) in North America and Europe. Such information would assist decision-makers at national and international levels in developing future public health programmes for managing IMD.

Methods: A comprehensive literature review was undertaken on 11 August 2020 across three databases: EMBASE, Medline and BIOSIS. Papers were included if they met the following criteria: full paper written in the English language; included patients aged ≥ 56 years; were published between 1/1/2009 11/9/2020 and included patients with either suspected or confirmed IMD or infection with N. meningitidis in North America or Europe. Case studies/reports/series were eligible for inclusion if they included persons in the age range of interest. Animal studies and letters to editors were excluded. In addition, the websites of international and national organisations and societies were also checked for relevant information.

Results: There were 5,364 citations identified in total, of which 76 publications were included in this review. We identified that older adults with IMD were mainly affected by serogroups W and Y, which are generally not the predominant strains in circulation in most countries. Older adults had the highest CFRs, probably linked to underlying comorbidities and more atypical presentations hindering appropriate timely management. In addition, there was some evidence of a shift in the incidence of IMD from younger to older adults.

Conclusions: The use of meningococcal vaccines that include coverage against serogroups W and Y in immunization programs for older adults needs to be evaluated to inform health authorities’ decisions of the relative benefits of vaccination and the utility of expanding national immunization programmes to this age group.

Keywords: Atypical Presentation, Clinical Burden, Epidemiology, Invasive Meningococcal Disease, Neisseria meningitidis, Older Adults, Recommendations, Serology

*Correspondence: Philipp.Oster@sanofi.com
1 Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
adolescents and young adults). Twelve different sero-
groups cause invasive meningococcal disease (IMD) [1] of
which six serogroups (A, B, C, W, X, and Y) are respon-
sible for most infections [2]. *Neisseria meningitidis* is one
of the leading causes of bacterial meningitis and sepsis
globally [3]; less common presentations include pneu-
monia and a number of other manifestations [3, 4]. The
case fatality rate of meningococcal disease remains high
(5–15%) despite treatment [5–7] and survivors can have
significante sequelae, with around 20% suffering long-
term disability [8]. IMD causes a substantial financial
burden, often associated with hospitalisation or ongoing
treatment of long-term sequelae [9–15], as well as nega-
tively impacting the quality of life of patients, their fami-
lies, caregivers and their extended networks [16, 17].

Vaccination remains the best strategy to prevent IMD
[2], and antibiotics are recommended for post-exposure
prophylaxis and treatment [18]. IMD is easily misdiag-
osed [18–20], because the severity of illness is often
obscured by non-specific symptoms [21], and presenta-
tion is similar to that of many self-limiting viral infec-
tions [22], or there are extra-meningeal foci of infections,
including pneumonia, pericarditis, epiglottitis and con-
junctivitis [23–25]. There is also a lack of confirmatory
testing available in many healthcare settings. Although
first-line antibiotics such as third generation cephalo-
sporins are still effective in the treatment of IMD, the
emergence of antibiotic-resistant strains have made IMD
management more complex. As a result, morbidity and
mortality rates have essentially remained unchanged over
the last two decades [24, 26–29].

The epidemiology of IMD varies markedly by region
and over time but there are an estimated 500,000 newly
diagnosed cases per annum [30]. The highest incidences
of IMD are found in countries in the African ‘meningitis
belt’ region, with the lowest incidences found in parts of
Europe and the Americas [3]. A recent systematic review
showed that serogroup B was responsible for the highest
proportion of *N. meningitidis* IMD cases worldwide; nev-
evertheless, the predominant serogroup varies by region,
country, age group and over time [31]. Vaccination
against IMD has also contributed to the shift in the pre-
dominant serogroups. For example, data from Italy [32],
Canada [33] and Germany [34] showed that following the
introduction of paediatric meningococcal C vaccination,
serogroup C cases in children declined, whilst the median
age of those affected by serogroup C increased. For exam-
ple, in Canada, the median age of cases increased from
16 years in 2003 to 42 years in 2006 [33]. There was also
an increased proportion of IMD cases caused by sero-
group Y (Germany and Canada) [33, 34] and serogroup B
and Y (Italy) [32]. Studies in Australia have also suggested
that following the introduction of childhood vaccination
against serogroup C, the proportion of notified cases in
those aged > 65 years increased [35], whilst studies in the
European Union (EU)/European Economic Area (EEA)
[36] and Italy [37] also suggested that cases in older
adults have increased. Taken together, this would suggest
a need to utilise multivalent vaccines and increase vac-
cine coverage beyond paediatric age groups to counteract
these trends.

These epidemiological shifts to older adults have also
highlighted the need for further investigation and exten-
sion of active surveillance systems (e.g. to include a
broader age population than those who are currently cov-
ered by national immunisation programs) to accurately
assess the changing epidemiology of IMD, and to inform
priorities for national health care systems and any associ-
ated future vaccination programmes [36–39]. There is
an acknowledgement that such data are currently lacking
[40].

To date, limited attention has been given to older
adults. As such, there is a lack of awareness of the disease
in this age group among healthcare professionals, and
older adults are not generally considered for immunisa-
tion against meningitis. The objective of our review was
to assess the published data on the epidemiology of IMD
in older adults (generally those aged ≥ 56 years) in North
America and Europe to examine how this has changed
over time, the impact it has had in terms of clinical bur-
den and mortality, and the extent of currently available
data. Such information would assist recommending bod-
ies at national and international levels in developing
future public health programmes for preventing IMD.

**Methods**

A search was undertaken on 11 August 2020 across three
databases: EMBASE, Medline and BIOSIS. The search
used MeSH, EMTREE and free text terms as applicable to
the databases. Citations were limited to those in English
language, in human subjects and published since 1 Janu-
ary 2009. A simplified version of the search strategy is
shown in Supplementary Table S1. Papers were included
if they met the following criteria: full paper written in the
English language (not just the abstract); included patients
aged ≥ 56 years; was published after 1 January 2009 but
before 11 August 2020; and included patients with either
suspected or confirmed IMD or infection with *N. menin-
gitidis* in North America or Europe. Case studies/reports/
series were eligible for inclusion if they included persons
in the age range of interest. Animal studies, non-English
language articles and letters to editors were excluded.
Review papers were checked to see if they reported pri-
mary data or included studies not captured by the data-
base searches, in which case the original papers were
ordered and considered for inclusion.
Three authors (KE, SG and PO) assessed the studies independently and discussed any papers for which there were disagreements as to their potential inclusion or exclusion. Data from studies which met the inclusion criteria were then entered into Microsoft Excel. Because the potential studies did not involve standardised study designs and the interventions and comparators were not relevant, only participant data and outcomes data were entered. Because the studies covered a wide range of countries and time periods and used various different methods to determine levels of IMD infection, it was felt that any attempt to combine studies in a formal meta-analysis would not be appropriate; therefore, the data extracted from the studies are discussed in a narrative format.

Additionally, the websites of the following international and national organisations and societies were also searched for relevant data on IMD in the age groups of interest: World Health Organization (WHO); European Centre for Disease Prevention and Control (ECDC); US Centers for Disease Control and Prevention (CDC); Active Bacterial Core Surveillance (ABCs); Emerging Infections Program Network; MenAfriNet; National Foundation for Infectious Diseases; Health Protection Scotland (HPS); Public Health England (PHE); National Institute for Health and Care Excellence (NICE); Institut Pasteur; Robert Koch Institut; Meningitis Research Foundation (MRF) & Meningitis Progress Tracker; Confederation of Meningitis Organisations (CoMO); Meningitis Now; Global Meningitis Genome Library; Infectious Diseases Society of America (IDSA); European Society of Clinical Microbiology and Infectious Diseases (ESCMID); International Society for Infectious Diseases (ISID); American Society for Microbiology (ASM); and European Society for Paediatric Infectious Diseases (ESPID).

**Results**

There were 5,351 citations identified. Following initial review, 505 papers (9% of the original search) plus 13 identified by searching the reference lists of these papers were obtained for full assessment. Following discussion among the authors, a total of 76 papers were included in this review. The reasons for exclusion are summarized in Fig. 1. Data extracted from each study/website was categorised within three headings, as containing data on epidemiology, atypical presentation or clinical burden of IMD (some contained data in multiple categories). Summary information on the published studies included (not including data taken from websites) can be found in

---

**Fig. 1 PRISMA Flow Diagram**

Records identified through databases searching (n = 5,351)

Additional records identified through other sources (n = 13)

Records after duplicates removed (n = 5,363)

Records screened (n = 5,363)

Records excluded (n = 4,858)

Full-text articles assessed for eligibility (n = 505)

Studies included in qualitative synthesis (n = 76)

Full-text articles excluded, with reasons

- n = 326 incorrect age group
- n = 83 No relevant data
- n = 11 Not European/N American data
- n = 8 Not English language full papers
- n = 1 Non-human study
Table 1. Publications we identified, which reported data from national or international organisations (e.g. CDC or ECDC), were not included in Table 1 if the organisation’s website provided more recent data which we have then presented below.

**Epidemiology**  
**Incidence & Prevalence**  
A number of studies/websites showed that, over time, an increasing proportion of IMD cases were in older adults, which may in part be because of improvements in surveillance programmes and as a consequence of meningococcal meningitis vaccination campaigns focusing almost exclusively on infants and adolescents. The Meningitis Progress Tracker [83] estimated that the global number of IMD cases had slowly increased in the period 2000–2017 (the latest year reported) in those aged 25–64 years (from 61,760 in 2000 to 72,430 in 2017) but remained relatively stable in those aged ≥ 65 years (from 2,469 in 2000 to 2,422 in 2017). According to recent estimates published as part of the Global Burden of Disease Study [41], the death rate, years of living with a disability (YLD) rate and incidence all increased in the oldest age groups, with meningococcal meningitis and ‘other’ meningitis causing most of the burden in those aged ≥ 80 years. It should be noted that both the Meningitis Progress Tracker and the Global Burden of Disease Study take estimates from the same sources available via the Institute of Health Metrics and Evaluation (IHME).

Data from Europe, available on the ECDC website for IMD [84], showed that whilst the overall numbers of confirmed IMD cases decreased in the EU/EEA area since 1999, the proportion of cases in those aged > 50 years rose markedly from just under 9% in 1999 to 32% in 2018 (the last year for which data are available). This may reflect the success of the meningococcal vaccination programmes and as a consequence of meningococcal meningitis vaccination campaigns focusing almost exclusively on infants and adolescents. The Meningitis Progress Tracker [83] estimated that the global number of IMD cases had slowly increased in the period 2000–2017 (the latest year reported) in those aged 25–64 years (from 61,760 in 2000 to 72,430 in 2017) but remained relatively stable in those aged ≥ 65 years (from 2,469 in 2000 to 2,422 in 2017). According to recent estimates published as part of the Global Burden of Disease Study [41], the death rate, years of living with a disability (YLD) rate and incidence all increased in the oldest age groups, with meningococcal meningitis and ‘other’ meningitis causing most of the burden in those aged ≥ 80 years. It should be noted that both the Meningitis Progress Tracker and the Global Burden of Disease Study take estimates from the same sources available via the Institute of Health Metrics and Evaluation (IHME).

Data from Europe, available on the ECDC website for IMD [84], showed that whilst the overall numbers of confirmed IMD cases decreased in the EU/EEA area since 1999, the proportion of cases in those aged > 50 years rose markedly from just under 9% in 1999 to 32% in 2018 (the last year for which data are available). This may reflect the success of the meningococcal vaccination programmes and as a consequence of meningococcal meningitis vaccination campaigns focusing almost exclusively on infants and adolescents. The Meningitis Progress Tracker [83] estimated that the global number of IMD cases had slowly increased in the period 2000–2017 (the latest year reported) in those aged 25–64 years (from 61,760 in 2000 to 72,430 in 2017) but remained relatively stable in those aged ≥ 65 years (from 2,469 in 2000 to 2,422 in 2017). According to recent estimates published as part of the Global Burden of Disease Study [41], the death rate, years of living with a disability (YLD) rate and incidence all increased in the oldest age groups, with meningococcal meningitis and ‘other’ meningitis causing most of the burden in those aged ≥ 80 years. It should be noted that both the Meningitis Progress Tracker and the Global Burden of Disease Study take estimates from the same sources available via the Institute of Health Metrics and Evaluation (IHME).

Data from Europe, available on the ECDC website for IMD [84], showed that whilst the overall numbers of confirmed IMD cases decreased in the EU/EEA area since 1999, the proportion of cases in those aged > 50 years rose markedly from just under 9% in 1999 to 32% in 2018 (the last year for which data are available). This may reflect the success of the meningococcal vaccination programmes and as a consequence of meningococcal meningitis vaccination campaigns focusing almost exclusively on infants and adolescents. The Meningitis Progress Tracker [83] estimated that the global number of IMD cases had slowly increased in the period 2000–2017 (the latest year reported) in those aged 25–64 years (from 61,760 in 2000 to 72,430 in 2017) but remained relatively stable in those aged ≥ 65 years (from 2,469 in 2000 to 2,422 in 2017). According to recent estimates published as part of the Global Burden of Disease Study [41], the death rate, years of living with a disability (YLD) rate and incidence all increased in the oldest age groups, with meningococcal meningitis and ‘other’ meningitis causing most of the burden in those aged ≥ 80 years. It should be noted that both the Meningitis Progress Tracker and the Global Burden of Disease Study take estimates from the same sources available via the Institute of Health Metrics and Evaluation (IHME).

Data from Europe, available on the ECDC website for IMD [84], showed that whilst the overall numbers of confirmed IMD cases decreased in the EU/EEA area since 1999, the proportion of cases in those aged > 50 years rose markedly from just under 9% in 1999 to 32% in 2018 (the last year for which data are available). 

Serogroups  
There were multiple studies/websites that showed infections caused by serogroups W and Y were more common in older adults than in young children and adolescents. According to data from the ECDC [84], the most prevalent serogroup in Europe during the period 1999–2018 was serogroup B (51% of cases and the dominant serogroup in all age groups below 65 years), with serogroups W and Y increasingly more prevalent in older adults over time. This may reflect the impact of serogroup C vaccinations over this period in teenagers and young adults, with some of the older adults benefitting from ‘herd protection’. A three-fold increase in the incidence of IMD caused by serogroup W was observed between 2013 and 2017, primarily because of increased cases in children aged < 5 years and adults aged ≥ 50 years. This increase in the incidence of IMD caused by serogroup W was confirmed by national institutions such as the Institut Pasteur [87] and many studies in European countries including those from the UK [42, 46, 47], Spain [48], Italy [49], the Netherlands [50, 51], and Sweden [44, 52]. One study in Ireland found serogroup Y as the predominant strain in those aged ≥ 65 years [53]. However, another from the Netherlands reported serogroup B as the most prevalent in older adults rather than serogroups W and Y [54].

Data from the CDC [86] showed that serogroup B was the dominant serogroup in the USA in those aged under 23 years, and serogroups A, C, W and Y were the dominant serogroups in adults and older adults (0.07 per 100,000 and 0.15 per 100,000 in those aged 25–64 years and ≥ 65 years, respectively, compared with 0.03 per 100,000 serogroup B infections in those aged 25–64 years). Latest surveillance data from the ABCs program network that included 10 states reported in 2018 that serogroup Y was more common in adults (aged ≥ 35 years) than in younger adults, in whom serogroups B and C were more frequent [88]. Several US studies also found serogroup Y to be more common in older adults [55–57], for example, Peruski et al. [56] noted that throughout the period 1988 to 2011, serogroup Y became an increasingly predominant cause of IMD in those aged ≥ 60 years, accounting for over 50% of all serogroups isolated in this age group after 1995. One possible explanation for this apparent increase in serogroup Y is that many of the cases in this age group were pneumonia with or without bacteraemia, and the latter are generally not considered to be cases of IMD.
| Publication                        | Study Dates | Country | Population | Meningitis confirmation | Key results                                                                                                                                 |
|-----------------------------------|-------------|---------|------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Global Burden of Disease Study 2018 [41] | 1990–2016   | Worldwide | All        | Varies by country        | Death rate and incidence increased, as did years of life lived with disability (YLD), in the oldest age groups (age groups up to >95 years), with other meningitis and meningococcal meningitis causing most of the burden in those aged ≥ 80 years. Meningococcus was the leading cause of meningitis mortality in 1990 (192,833 deaths [95% UI 153,358–221,503] globally), Globally in 2016, 1.48 million (1.04–1.96) YLDs were due to meningitis compared with 21.87 million (18.20–28.28) disability-adjusted life-years (DALYs). |
| Gray et al. 2019 [42]             | 1998–2019   | UK      | 525–2573 cases per annum | Notified cases to PHE. Mix of PCR test, culture test and PCR/culture testing | The age profile of meningococcal disease cases altered in 2017/18, with an increased proportion of cases in those aged ≥ 45 years. This was subsequent to increases in serogroup W and Y cases, together with the decrease in serogroup B disease |
| Stefanelli et al. 2015 [43]       | 1994–2014   | Italy   | 174 IMD cases, out of 4,263 nationally reported (www.iss.mabi), occurred in Puglia | PCR or antisera | Since 2013, 52% of the IMD cases occurred among patients aged ≥ 45 years. The CFR in those aged ≥ 65 was 19% |
| Publication          | Study Dates       | Country  | Population                                                                 | Meningitis confirmation | Key results                                                                                                                                 |
|---------------------|-------------------|----------|----------------------------------------------------------------------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Säll et al. 2017 [44] | 1995–2012         | Sweden   | A total of 191 patients with serogroup Y IMD were identified in Sweden during the 1995–2012 study period. Of the 191 known episodes of serogroup Y IMD during the study period, medical records for 175 (92%) patients were retrospectively and systematically reviewed. For technical reasons, 16 medical records could not be found, the majority from 1995 to 1999. The median age of the 175 patients in the study was 62 years, and two distinct age groups, 11–20 years and patients > 60 years, together represented the majority of cases (73% of all patients). Four patients were < 5 years of age and only one was < 1 year. Meningitis was diagnosed in 33% and pneumonia in 19% of all patients. | Lab confirmed           | Two distinct age groups, 11–20 years and > 60 years, together represented the majority of cases (73% of all patients). This age distribution reflects the change in meningococcal epidemiology in Sweden where IMD now largely affects the elderly, with serogroup Y predominating. |
| Folaranmi et al. 2017 [45] | Evaluation of data from January 2012–June 2015 | USA      | Incidence of MSM in the USA | Meningococcal disease data from the National Notifiable Disease Surveillance System | Within the oldest age group (56–64 years) there was just 1 case out of a total of 527 total cases. |
| Edge et al. 2016 [46]   | 2007–2011         | UK       | IMD cases confirmed by PHE were linked with national hospital records and death registries | Clinical presentation by interrogation of ICD-10 codes | Atypical clinical presentations, including pneumonia and septic arthritis, mainly occurred among those aged ≥ 65 years, caused mainly by serogroups W and Y. CFR varied by serogroup and increased with age group, but no significant associations were identified in the multivariable logistic regression models. However, older adults and those with serogroup Y disease were significantly and independently more likely to develop meningococcal pneumonia. |
| Campbell et al. 2020 [47] | 2014              | UK       | 340 laboratory-confirmed IMD cases caused by serogroups B (179 cases), W (95 cases) and Y (66 cases) in individuals aged ≥ 5 years | There were 184 (54%) cases confirmed by culture only, 110 (32%) by PCR only and 46 (14%) by both methods | |
Table 1 (continued)

| Publication               | Study Dates     | Country    | Population  | Meningitis confirmation | Key results                                                                 |
|---------------------------|-----------------|------------|-------------|--------------------------|-----------------------------------------------------------------------------|
| Ortiz de Zárate et al. 2016 [48] | 1995–2014       | Spain      | 675 invasive N. meningitidis isolates were analysed during the study period | Lab confirmed isolates                                                     | Serogroup Y isolates were the most frequent among the elderly aged ≥ 65 years |
| Parisi et al. 2019 [49]   | 2011–2017       | Italy      | IMDs surveillance data from the Italian National Health Institute | Presumably notified cases but not explicitly stated                       | The overall IMDs incidence increased from 0.25 cases/100,000 inhabitants in 2011 to 0.33 in 2017. The increased number of cases in adults and elderly was mostly due to serogroups C, W and Y. |
| Stoof et al. 2015 [50]    | 1999–2011       | The Netherlands | A retrospective study using Dutch surveillance data on IMD from June 1999 to June 2011. Clinical information was retrieved from hospital records. Between June 1999 and June 2011, the NRLBM received 939 isolates from the nine sentinel laboratories. Hospital records were retrieved from 879 (94%) of these IMD cases | Lab confirmed                                                              | The overall CFR in this study was 8% and higher for adults compared with children with a clear peak in patients aged ≥ 65 years |
| Loenenbach et al. 2019 [51] | 2015–2018       | The Netherlands | A total of 565 IMD cases were reported | Lab confirmed                                                              | In patients aged ≥ 65 years, CFR overall for this age group was 8.2% (12/146). In patients aged 20–64 years, the CFR overall was 10.2 (18/176). |
| Eriksson et al. 2018 [52] | January 1995–June 2017 | Sweden | N = 89 IMD cases at the National Reference Laboratory for Neisseria meningitidis | Whole genome sequencing                                                     | In recent years, a significant increase in the incidence of serogroup W has been noted in Sweden, to an average incidence of 0.15 case/100,000 population in 2015 to 2016. In 2017 (1 January to 30 June), 33% of IMD cases (7/21 cases) were caused by serogroup W. |
| Bennett et al. 2019 [53]  | 1996/1997 and 2015/2016 | Ireland | 3,707 cases were reported | National surveillance data on laboratory-confirmed cases | CFR was highest in patients aged ≥ 65 years (15.7%; RR 3.73, 95% CI 2.25–6.19; P < 0.0001), although the incidence of IMD was one of the lowest in that age group. |
| Publication                  | Study Dates               | Country              | Population                                                                 | Meningitis confirmation | Key results                                                                                                                                 |
|-----------------------------|---------------------------|----------------------|-----------------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Bijlsma et al. 2014 [54]    | 1998–2002 compared with  | The Netherlands      | A total of 814 patients were included for analysis                         | Patients from NRLBM     | A figure within the publication breaks out the only data for patients 55 years old and above (data presented for reported cases over the whole study period) and presents an overall incidence rate of approximately 0.2 in those aged 55 years rising to approximately 0.7 in those aged ≥ 90 years |
| Clarke & Mallonee. 2009 [55]| 1988–2004                 | USA                  | Cases from the state-wide passive reporting system with disease onset between 1988 and 2004 were included | Passive surveillance    | In the ≥ 65-year-old age group, 545 cases of IMD occurred in Oklahoma; 71 (13.0%) died. In those aged > 40 years, serogroup Y was most common (54.6%) followed by B, C and W-135 |
| Peruski et al. 2014 [56]    | 1988–2011                 | USA                  | 1,258 cases of IMD were reported to MDPH                                   | Lab confirmed           | Throughout the 24-year time period between 1988 and 2011, serogroup Y became increasingly predominant in IMD cases in those aged ≥ 60 years accounting for over 50% of all serogroup isolates in this age group after 1995 |
| Baccarini et al. 2013 [57]  | 1945–2010                 | United States and Canada | Review of different studies over the last half century                     | Varies by study         | The distribution of IMD by age was similar in both the USA and Canada. Serogroup Y was proportionally more frequent in adults aged > 65 years in both countries, accounting for over 50% of IMD cases in this age group |
| Publication                      | Study Dates | Country | Population                                                                 | Meningitis confirmation | Key results                                                                                                                                 |
|---------------------------------|-------------|---------|----------------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Perea-Milla et al. 2009 [27]     | 1995–2000   | Spain   | 848 patients diagnosed with IMD from 1995 to 2000 in Andalusia and the Canary Islands, Spain | ICD code and some PCR confirmed | A total of 323 patients (38.1%) had sepsis, 336 (39.6%) meningitis and the rest a mixed clinical form, with mortality rates of 10.7%, 2.1% and 4.2%, respectively (P < 0.001). Sepsis vs. the other clinical forms had an OR for death of 4. The results showed that the older the patient, the greater the mortality, with 4.9% deaths in patients aged under 11 years vs. 25% deaths in those aged > 65 years |
| Gil-Prieto et al. 2011 [58]     | 1997–2008   | Spain   | Total of n = 6,131 cases                                                  | 0360 meningococcal meningitis code | The CFR increased dramatically with age in meningococcal infection, meningococcal meningitis and meningococcaemia (P < 0.001) reaching the highest values in the > 85-year-old group with 37.66% (95% CI: 26.84–48.49), 42.42% (95% CI: 25.56–59.29) and 37.14% (95% CI: 21.13–53.15) for meningococcal infection, meningococcal meningitis and meningococcaemia, respectively |
| Cabellos et al. 2009 [59]       | 1977–2006   | Spain   | Prospective study at a 1,000 bed teaching hospital in Barcelona, Spain. Since 1997, all episodes of community-acquired bacterial meningitis were recorded for cases occurring in patients ≥ 65 years old and these were compared with community-acquired bacterial meningitis occurring in those aged < 65 years | Lab confirmed | There were 675 episodes of meningitis in adults (aged ≥ 18 years) recorded. Of these, 185 (27%) were aged ≥ 65 years (range, 65–93 years). In general, bacterial meningitis in those aged ≥ 65 years was more difficult to diagnose because of the absence of meningeal signs, but the disease had greater neurologic severity and higher rates of complications and mortality |
| Goldacre & Maisonneuve, 2013 [60]| 1999–2010   | UK      | 19,113 people admitted to hospital for meningococcal disease             | all people with a discharge diagnosis in HES of meningococcal disease (code A39 in the 10th revision of the ICD, code 036 in the 9th revision) from 1999 to 30 September 2010 | OR of CFR by age group: 55–59 years: 6.66, 60–64 years: 5.11, 65–69 years: 8.98, 70–74 years: 7.5, 75–79 years: 8.08, > 80 years: 9.92 |
| Publication                  | Study Dates     | Country                  | Population                                                                 | Meningitis confirmation | Key results                                                                                                                                                                                                 |
|-----------------------------|-----------------|--------------------------|-----------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Parent du Chatelet et al.   | 2011–2015       | France                   | 5,690 cases were biologically confirmed. For 85 (1.5%) cases, the confirmation technique was not reported despite an available group result | Lab confirmed           | The CFR was higher in adults ≥ 60 years old (20%) than in the other age groups (9.9% in infants, 8.9% in 1–4 year-olds, 5.9% in 5–14 year-olds, 9.3% in 25–59 year-olds)                                               |
| Bai et al. 2019 [62]        | 2019            | Eastern Europe but relevant age-specific data for Poland | Findings from Global Round Table Initiative in East Europe                  | Lab confirmed           | CFRs ranged from approximately 3% to 30% both within and across the Eastern European countries represented. In Poland, the greatest CFR (44%) was noted in individuals aged > 65 years                                          |
| Skoczyńska et al. 2013 [63] | 2013 paper analysing data from 2002–2011 | Poland                   | Invasive meningococcal data collected between 2002 and 2011 in the National Reference Centre for Bacterial Meningitis | The isolates were re-identified and characterised by susceptibility testing, MLST analysis, porA and fetA sequencing. A PCR technique was used for meningococcal identification directly from clinical materials | The general CFR was 10.0% for cases with known outcome only, and was highest in patients aged > 65 years (46.2%, P = 0.001), although the incidence of IMD was lowest in that age group. Although not broken down by age, the highest CFR was found in patients with sepsis (22.4%), as compared with patients with meningitis and sepsis (7.0%, P = 0.0007) and with meningitis alone (3.1%, P < 0.0001) |
| Beebeejaun et al. 2020 [64] | 2020 paper based on 2008–2015 data | England                  | Analysis of surveillance data of laboratory-confirmed IMD cases diagnosed 2008–2015 matched to death registrations | Lab confirmed           | In older adults aged ≥ 65 years, all 114 and 134 deaths within one and seven days after diagnosis were IMD-related, as were 96% (146/152) of deaths within 30 days of diagnosis. More than half of the IMD-related fatalities amongst serogroup W cases (44/84, 52%) were in those aged ≥ 65 years and 47/70 (67%) of the IMD-related fatalities amongst serogroup Y cases were in those aged ≥ 65 years |

Table 1 (continued)
### Table 1 (continued)

| Publication | Study Dates | Country | Population | Meningitis confirmation | Key results |
|-------------|-------------|---------|------------|-------------------------|-------------|
| Knol et al. 2017 [65] | 2017 paper using surveillance data from 1992–93 to 2015–16 | The Netherlands and England | Observational cohort study using surveillance data for the Netherlands and England | Lab confirmed | In the Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 2015–16 compared with 2014–15, with an incidence rate ratio of 5·2 (95% CI: 2·0–13·5) and 11% case fatality. In England, the incidence increased substantially in 2012–13 compared with 2011–12, with an incidence rate ratio of 1·8 (95% CI: 1·2–2·8) |
| Masson-Behar et al. 2017 [66] | 2011–2016 | France | A 5-year retrospective study. Included all patients with inflammatory joint symptoms and proven meningococcal disease. A total of 7 patients (5 males) with joint symptoms and meningococcal disease were identified. Of these, 2 had meningitis | Identification of Neisseria meningitidis in blood, cerebrospinal fluid, or synovial fluid | Patients presented initially with arthritis |
| Cikirikcioglu, et al. 2017. [67] | 2017 | Switzerland | A 55-year-old woman with a history of high fever was admitted to the center and hospitalized with the diagnosis of bronchopneumonia. Transthoracic echocardiography showed severe aortic valve regurgitation with a mobile vegetation and abscess cavity underneath the left main stem | PCR test | Patient presented with endocarditis |
| Bajaj et al. 2019 [68] | Not explicitly stated. Year of publication was 2019 | USA | A 61-year-old woman with past medical history of diabetes and hypertension presented with fever, chills and headache of 1 day duration | Lab confirmed | This was the fourth case of intraventricular empyema reported secondary to Neisseria meningitidis |
| Keeley et al. 2018 [69] | 2018 | UK | A 74-year-old Caucasian woman with no history of immunosuppression or rheumatological disease, but with a history of paroxysmal atrial fibrillation for which she was taking flecainide but no anticoagulation, was admitted following a Baltic cruise holiday | PCR confirmed | Patient presented as myopericarditis |
| Publication                         | Study Dates | Country | Population                                                                 | Meningitis confirmation | Key results                                                                 |
|------------------------------------|-------------|---------|-----------------------------------------------------------------------------|-------------------------|------------------------------------------------------------------------------|
| Walayat et al. 2018 [70]           | 2018        | USA     | The case of a 72-year-old man with a past medical history of severe COPD, obstructive sleep apnoea, and stage I lung cancer status post-stereotactic body radiation therapy 1 year ago | PCR confirmed           | Patient presented with a 6-day history of productive cough with yellowish sputum, shortness of breath, extreme myalgia, and fatigue |
| Romero-Gomez et al. 2012 [71]      | 2011        | Spain   | A 94-year-old man sought medical care for left-sided chest pain and difficulty in breathing that began 1 day before admission. He had been healthy until 4 days before admission, when he had sore throat, rhinorrhoea, mild cough, and muscle pain. He had a medical history of ischemic cardiopathy | By the VITEK NHI Identification card and by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry | Patient presented with bacteraemic pneumonia                                  |
| Singh & Swann. 2013 [72]           | 2013        | UK      | A 55-year-old female non-smoker with meningococcal septicemia was treated in an intensive care unit for 11 days, requiring assisted ventilation and renal dialysis. She developed several lesions of necrosis affecting the skin on her arms and legs, as well as ischemic necrosis to her fingers and feet | Not specified in paper   | Patient recovered with no requirement for amputation following antibiotic treatment of IMD |
| Arnáiz-García, et al. 2017 [73]    | 2017        | Spain   | A 78-year-old diabetic woman was admitted to the institution presenting fever, diarrhoea, vomiting, and abdominal pain. The patient reported the appearance of red and purplish macules over her lower extremities within the last 4 h Gram-negative diplococci, later reported as *Neisseria meningitidis*, was isolated from blood and cerebrospinal fluid cultures | Confirmed by lab test   | She presented leucocytosis, thrombocytopenia, renal insufficiency, acidosis, and hypoxia cutaneous lesions evolved to haemorrhages and ecchymosis in both hands and feet |
| Zimmermann & Chmiel 2018 [74]      | 2018        | Switzerland | A 78-year-old woman with a known history of hypertensive cardiomyopathy and paroxysmal benign positional vertigo presented to the emergency department with a 5-day history of throat pain and hoarseness, as well as a progressive and dolorous swelling in the submandibular area | Confirmed by lab test   | Patient presented with acute epiglottitis                                    |
| Publication          | Study Dates | Country     | Population                                                                                      | Meningitis confirmation | Key results                                      |
|---------------------|-------------|-------------|------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------------|
| Rosenfield et al. 2017 [75] | Not explicitly stated. Year of publication was 2017 | Canada       | A 56-year-old Caucasian woman with past history of severe Neisseria meningitides meningitis and bacteraemia at age 42 years, presented with a 2-day history of feeling unwell with vomiting and loose stools | Lab confirmed           | Patient presented with terminal complement deficiency |
| Lesourd et al. 2018 [76] | 2018        | France      | A 85-year-old man was allocated to the emergency department based on an initial fever at home. His previous history included atrial fibrillation, renal lithiasis and benign prostatic hyperplasia | Lab confirmed           | Patient presented with primary bacterial ventriculitis |
| Lawler et al. 2019 [77]  | 2015        | UK          | In 2015, two cases of serogroup W135 occurred in residents aged ≥ 85 years at a 46-bed elderly care home in North East England over a 7-month period; both cases had single bedrooms | N. meningitidis was isolated from blood cultures collected on admission | Case 1 was admitted to hospital with acute respiratory distress and fever (temperature 41 °C). Case 2 was admitted to hospital with acute onset of fever, tachycardia and hypotension and was treated for respiratory sepsis unsuccessfully |
| Puleston et al. 2012 [78] | 2012        | England     | 5 people involved in an outbreak in a healthcare setting | Lab confirmed           | The 3 confirmed cases all presented with respiratory symptoms |
| Russcher et al. 2017 [79] | 2017        | The Netherlands | A man in his early 60s consulted his general practitioner (GP) because of a painful, red and swollen ankle | Confirmed by tissue culture | Patient presented with necrotising fasciitis |
| Ladhani et al. 2012 [80] | 2007–2009   | England and Wales | 34 cases in 2007 to 44 in 2008 and 65 in 2009 | Lab confirmed           | There were 162 laboratory-confirmed W-135 cases reported during 2006–2012 (of which about 44% occurred in those aged > 45 years). Most serogroup W-135 infections in older adults presented as pneumonia (usually in the presence of comorbidities). Fatalities occurred in 5.5% of these cases, all in adults older than 45 years. Based on the graph presented, the CFR would appear to be > 0.1 in those aged 45–64 and < 0.2 in those aged ≥ 65 years |
Table 1 (continued)

| Publication      | Study Dates | Country | Population | Meningitis confirmation | Key results                                                                 |
|------------------|-------------|---------|------------|-------------------------|-----------------------------------------------------------------------------|
| Ristic et al. 2012 [81] | 2000–2009   | Serbia | There were 94 registered cases | Laboratory confirmed in 34% (32/94 persons) | The CFR in this period was 13.8% (septicaemia 26.1% meningitis 2.1%). The data for meningitis was only reported by two age groups (< 14 years of age and ≥ 15). Of the 48 cases of meningitis, only 12 were in the older group but the age range was not stated. There was one fatality in those aged ≥ 15 years for a CFR of 8.3% (compared with an overall CFR in meningitis of 2.1% for all ages combined) |

**Clinical burden**

| Pellegrino et al. 2014 [82] | 1993–2011 | USA    | Two large inpatient databases | Estimated the number of cases of meningococcal meningitis and other bacterial meningitides | The incidence of hospitalisations for meningococcal meningitis (estimated from the publication) were approximately 5 per 100,000 in the 45–64-year age group, 8 in the 65–84-year age group, and 12 in the ≥ 85-years age group |

CFR Case Fatality Rate, CI Confidence Interval, COPD Chronic Obstructive Pulmonary Disease, DALY Disability-Adjusted Life Years, HES Hospital Episode Statistics, ICD International Classification of Diseases, IMD Invasive Meningococcal Disease, IQR Interquartile Range, MDPH Massachusetts Department of Public Health, MLST Multilocus Sequence Typing, MSM Men who have Sex with Men, NRLBM Netherlands Reference Laboratory for Bacterial Meningitis, OR Odds Ratio, PCR Polymerase Chain Reaction, PHE Public Health England, RR Risk Ratio, UI Uncertainty Intervals, YLD Years Lived with Disability
Therefore, underreporting of other serogroups may have caused an apparent increase in serogroup Y cases as a proportion of all cases.

Mortality
Many of the studies showed that case fatality rates (CFRs) were higher in older adults than in younger adults, adolescents and children. Global data over the period 2000 to 2017 from the Meningitis Research Foundation’s Meningitis Progress Tracker [83] showed that the CFR for those aged ≥65 years averaged 12% compared with 7% for those aged 25–64 years.

Data from the ECDC [84] (during the period 1999–2018) showed that the CFR in those aged ≥50 years remained relatively stable at 17.4–18.4% from 1999 to 2006 but decreased to approximately 14% in recent years. Multiple published studies in Europe also found higher CFRs in older adults, including those from Spain [27, 58, 59], UK [46, 60, 78], Ireland [53], France [61] and the Netherlands [50]. These studies highlighted that existing comorbidities were an additional risk factor, and combining these with increased age may explain the poorer outcome in older adults. Eastern Europe appears to have much higher CFRs – ranging from approximately 3–46% [62, 63]. However, one single study undertaken in the Netherlands during 2015–2018 found higher CFRs in younger, rather than older, adults [51].

The 2018 surveillance report from the CDC [86] in the USA showed higher CFRs in patients aged ≥65 years than in those aged 25–64 years (23.3 per 100 cases vs 14.1 per 100 cases). The CFRs were higher in these two age groups (25–64 and ≥65 years) than in any other age group, including infants (overall average CFR was 12.0 per 100 cases). Other US studies support the higher CFRs observed in older adults [55, 56].

CFRs may also be higher in those affected by serogroups W and Y, which as shown previously are more frequently the cause of an additional risk factor, and combining these with increased age may explain the poorer outcome in older adults. Eastern Europe appears to have much higher CFRs – ranging from approximately 3–46% [62, 63]. However, one single study undertaken in the Netherlands during 2015–2018 found higher CFRs in younger, rather than older, adults [51].

The 2018 surveillance report from the CDC [86] in the USA showed higher CFRs in patients aged ≥65 years than in those aged 25–64 years (23.3 per 100 cases vs 14.1 per 100 cases). The CFRs were higher in these two age groups (25–64 and ≥65 years) than in any other age group, including infants (overall average CFR was 12.0 per 100 cases). Other US studies support the higher CFRs observed in older adults [55, 56].

CFRs may also be higher in those affected by serogroups W and Y, which as shown previously are more frequently the cause of an additional risk factor, and combining these with increased age may explain the poorer outcome in older adults. Eastern Europe appears to have much higher CFRs – ranging from approximately 3–46% [62, 63]. However, one single study undertaken in the Netherlands during 2015–2018 found higher CFRs in younger, rather than older, adults [51].

Atypical clinical presentation
We identified 20 case reports (12 females, 6 males and 2 cases where sex was not reported) from 17 papers [66–77, 79] concerning patients aged ≥55 years (range 55–94 years) presenting with atypical symptoms (often linked to a comorbid condition) including myocarditis/
There is likely considerable underreporting of IMD cases worldwide. The MRF [83] noted that because meningitis deaths are based on national death registration rather than national surveillance estimates and that because 97% of cases occur in countries with either no or low quality data recording systems, the number of deaths would be substantially underestimated (although it should be noted this comment applies to meningitis in general and not that caused solely by Neisseria meningitidis). Improved surveillance systems could help improve disease monitoring. The Global Burden of Disease Study showed that six of the ten countries with the highest number of meningitis deaths (all-causes) are in the African meningitis belt region; though data for older adults from these countries are lacking, suggesting a potential underreporting of cases in older adults in this region [41, 91, 92]. Since we restricted our search to English language papers only we decided to exclude date from outside North America and Europe but it is interesting to note that we identified only eleven English language published studies of IMD in older adults from countries outside Europe or North America, which appears to be consistent with previous research highlighting the lack of regional data, particularly from South-East Asia and the Eastern Mediterranean [3] in non-native languages. It is also interesting to note that some of the data from these studies was consistent with the findings from Europe and North America with respect to serology and the shift in the incidence to older age groups [93, 94]. In addition, many of the publications identified in this review, despite having patients in the age group of interest, did not present data on clinical presentation and/or serogroups by age (and indeed when they did present these data, they tended to focus specifically on younger adults) or they presented all meningitis cases together without distinction by pathogenic cause [51, 95-100].

There is evidence to suggest that some risk groups are underrepresented in this review. It is worth noting that IMD cases in MSM are reported as a specific category within the CDC data, and multiple studies in this group have previously been published [101, 102]. There is evidence that younger men are more willing to be vaccinated than older men[103]. However, only a single study in this group was identified in the literature review and only one patient fell within the age range of interest, suggesting the predominant focus is possibly on younger men [45]. It also surprising that, with the exception of two case reports [77], there were no studies examining older adults living in nursing or residential care homes, where one might suspect that close contact between individuals could potentially lead to an increase in transmission of infectious diseases such as IMD.

Of note, the high CFRs observed in older adults in studies included in this review, up to 34% [104], are consistent with those reported in a recent meta-analysis of laboratory-confirmed IMD. In addition, the meta-analysis also showed that CFRs generally increased with age and were highest in the oldest age groups [90]. As such, older adults represent an unmet need for meningococcal vaccination because, as noted by Trezikowski de Lima et al. [105] "given the increasing proportion of older people in the population and the high CFR of meningococcal disease in the elderly, it would be interesting to evaluate the insertion of these vaccines in the immunization programs for this age group...also, vaccines can generate other benefits, e.g. lower overall cost of healthcare".

The strengths of this study were that it included a comprehensive literature review and grey literature search to supplement the data derived from publications. However, there was relatively little information on IMD in older adults, and the difficulties of interpreting the results were compounded by the inconsistent reporting by age group, or where demographic breakdown of a study population was presented in detail the subsequent results (e.g. epidemiology, clinical presentations) were only presented for the cohort as a whole. The issue is further complicated by the lack of standardised case definitions, changes to national immunisation programmes over time and the varying surveillance and laboratory techniques employed worldwide, as commonly acknowledged [106, 107]. As such, there remains the need for more specific age-related studies and improvements in consistency of reporting across all age groups, including older adults [108, 109].

It should also be noted that the data presented here predate the severe acute respiratory syndrome coronavirus 2 pandemic and the introduction of coronavirus disease 2019 (COVID-19) control measures; social distancing and shielding appear to have led to a decrease in recorded cases of IMD in some countries [110]. However, IMD cases that were associated with respiratory presentations of which some corresponded to suspected COVID-19 appeared to increase in 2020 compared with 2018 ($P=0.029$) and 2019 ($P=0.002$) and involved the elderly and with unusual isolates [111]. Moreover, IMD concomitant with COVID-19 may be associated with poorer outcomes in the elderly, because the prognosis of either disease is usually worse in this age group, though definitive data are lacking. Nonetheless, IMD burden would likely return to previous levels once on-going COVID-19 measures are relaxed, and as such continued surveillance for meningococcal and invasive bacterial infections will also be important.
as the pandemic progresses. The authors of the latter study [111] concluded that surveillance of IMD should be improved and vaccination against meningococcal disease in older adults should be considered (currently only Italy suggests adopting a lifelong approach to vaccination, with regular immunisation being offered to adults in the future) [112].

Conclusions
This comprehensive literature review, supplemented by data from national organisations, institutions and societies provides evidence that older adults (those aged ≥ 55 years) with IMD are mainly affected by serogroups W and Y, which are generally not the predominant strains in circulation in any country. Older adults have the highest CFRs, probably linked to underlying comorbidities and more atypical presentations hindering appropriate timely diagnosis and management. In addition, there has been a shift in the incidence of IMD from younger to older adults, which may be attributed to the success of meningococcal vaccination programmes, although the exact scale of this shift is difficult to quantify. Future research should evaluate the alternative options of either implementing adolescent vaccination programmes with conjugate vaccines in some countries that may lead to indirect protection in older adults or the use of meningococcal vaccines that include coverage against serogroups W and Y in immunization programs for older adults to help inform health authorities’ decisions of the benefits of vaccination and the utility of expanding national immunization programmes to extend protection to older adults.

Abbreviations
ABCs: Active Bacterial Core surveillance; ASM: American Society for Microbiology; CDC: Centers for Disease Control and Prevention; CFR: Case Fatality Rate; 95% CI: 95% Confidence Interval; CoMo: Confederation of Meningitis Organisations; COVID-19: Coronavirus disease 2019; ECDC: European Centre for Disease Prevention and Control; EEA: European Economic Area; ESCMID: European Society of Clinical Microbiology and Infectious Diseases; ESPID: European Society for Paediatric Infectious Diseases; EU: European Union; HPS: Health Protection Scotland; IDSA: Infectious Diseases Society of America; IHME: Institute for Health Metrics and Evaluation; IMD: Invasive Meningococcal Disease; ISID: International Society for Infectious Diseases; MRF: Meningitis Research Foundation; MSM: Men who have Sex with Men; NICE: National Institute for Health and Care Excellence; PHE: Public Health England; UK: United Kingdom; USA: United States of America; WHO: World Health Organization; YLD: Years of Life lived with Disability.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-12795-9.

Additional file 1.

Acknowledgements
The authors acknowledge Richard Glover and Tim Mills of InScience Communications, Springer Healthcare Ltd, Chester, UK for editorial assistance with the preparation of this manuscript. This assistance was funded by Sanofi Pasteur. The authors also thank Jean-Sebastien Perciso for editorial assistance and manuscript coordination on behalf of Sanofi Pasteur.

Authors’ contributions
SG – Conceptualization, methodology, investigation, Writing – review and editing. IBG – Methodology, investigation, Writing – review and editing. KE – methodology, investigation, Writing – review and editing. FC – investigation, Writing – review and editing. PO – Conceptualization, methodology, investigation, Writing – review and editing. The author(s) read and approved the final manuscript.

Funding
This review was funded by Sanofi Pasteur.

Availability of data and materials
All data generated or analysed during this study from published articles or conference presentations are included in this published article (Table 1). Any data generated or analysed from international or national organisations is available from the weblinks presented in Supplementary Table 2.

Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
PO, FC and IBG are employees of Sanofi Pasteur and may hold shares in the company. SG was an employee of Sanofi Pasteur at the time of this review. KE is an employee of InScience Communications, Springer Healthcare Ltd, Chester, UK, which was contracted by Sanofi Pasteur to undertake the literature searches and provide editorial assistance.

Author details
1Sanofi Pasteur, 14 Espace Henry Vallée, 69007 Lyon, France; 2InScience Communications, Chester, UK.

Received: 30 September 2021 Accepted: 10 February 2022

References
1. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(3):2.
2. Hedari CP, Khinkary RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist. 2014;7:85–99.
3. Jafari RZ, Ali A, Messonnier NE, Tevi-Beissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.
4. Strelow VL, Vidal JE. Invasive meningococcal disease. Arq Neuropsiquiatr. 2013;71(98):653–8.
5. Raja NS, Parasakthi N, Puthucheary SD, Kamarulzaman A. Invasive meningococcal disease in the University of Malaya Medical Centre, Kuala Lumpur. Malaysia J Postgrad Med. 2006;52(1):23–9 discussion 29.
6. Fransen F, Heckenberg SGB, Hamstra HJ, Feller M, Boog CJF, van Putten JPM, van der Beek D, van der Ende A, van der Ley P. Naturally occurring lipid A mutants in Neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog. 2009;5(4):e1000396.
7. Kinlin LM, Spain CV, Ny L, Johnson CC, White ANJ, Fisman DN. Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales. Am J Epidemiol. 2009;169(5):588–95.

8. Sadarangani M, Scheifele DW, Halperin SA, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Safadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36.

9. Nadel S, Nisius N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.

10. Wang H, Afzali B, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine. 2014;32(37):4791–8.

11. Wang B, Santorenoes R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36(10):1201–22.

12. Rampilakis E, Vaiannicourt J, Murseke S, Sampalis JS. Healthcare resource utilization and cost of invasive meningococcal disease in Ontario Canada. Pediatr Infect Dis J. 2019;38(3):253–7.

13. Scholz S, Koerber F, Meszaros K, Frosch M, Vogel U. Emergency department and hospital costs caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(12):1692–701.

14. Wang B, Haji Ali Afzali H, Giles L, Marshall H. Lifetime costs of invasive meningococcal disease: a markov model approach. Vaccine. 2019;37(46):6885–93.

15. Huang L, Heuer OD, Janßen B, Hächl D, Schmedt N. Clinical and economic burden of invasive meningococcal disease: evidence from a large German claims database. PLoS One. 2020;15(1):e0228820.

16. Strifler L, Morris SK, Dang V, Tu HAT, Minhas RS, Jamieson FB, Deeks SL, Tu HAT, Minhas RS, Jamieson FB, Deeks SL. Economic burden of invasive meningococcal disease: a systematic review. J Pediatr Infect Dis Soc. 2016;5(4):417–30.

17. Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38.

18. Bröker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive meningococcal disease. Infect Drug Resist. 2011;4:13–47.

19. Bronska E, Kalmusova J, Dzuvova G, Marofova V, Koz P, Benes J. Dynamic of PCR-based diagnosis in patients with invasive meningococcal disease. Clin Microbiol Infect. 2006;12(2):137–41.

20. Garlicki A, Bociqga-Jasik M, Kalinowska-Nowak A. Invasive meningococcal disease: management and treatment. Przegl Epidemiol. 2008;62(Suppl 1):39–44.

21. Stinson C, Presa J, Abalos M. Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci. J Pediatric Infect Dis Soc. 2016;5(4):366–70.

22. GBD 2016 Meningitis Collaborators. Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1061–82.

23. Gray S, Campbell H, Walker A, Patel S, Willerton L, Lekshmi A, Bai X, Ribeiro S, Parikh S et al. Epidemiology and surveillance of meningococcal disease: Epidemio Infect. 2016;144(14):3032–7.

24. Marten O, Koerber F, Bloomp D, Bullinger M, Bussey C, Christensen H, de Wals P, Dohmna-Schwake C, Henneke P, Kirchner M, et al. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease. Health Qual Life Outcomes. 2019;17(1):87.

25. Fularanami TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A, Antivi M, Dorsinville M, Pacilli M, Smith S, et al. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012–2015. Clin Infect Dis. 2016;63(Suppl 7):S756–63.

26. Edge C, Waith JP, Ribeiro S, Borrow R, Ramsay M, Ladham S. Clinical diagnoses and outcomes of 4619 hospitalised cases of meningococcal disease, adjusting for indication bias. BMC Public Health. 2009;9:95.
laboratory-confirmed invasive meningococcal disease in England: linkage analysis of multiple national databases. J Infect. 2016;73(5):427–36.

47. Campbell H, Andrews N, Parikh S, Ribeiro S, Gray S, Lucidarme J, Ramsay ME, Borrow R, Ladhan S. Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England. J Infect. 2020;80(2):182–9.

48. Ortiz de Zárate J, Arana M, Asercor M, Mojica C, Talleron E. Epidemiology and characterization of invasive Neisseria meningitidis serogroup Y isolates in Basque country (Northern Spain) from 1995 to 2014. 2016. https://www.escmrd.org/escmrd_publications/escmrd_eli brary/mater ial/?mid=45891. Accessed 24 Mar 2021. In: vol. 2021; 2016.

49. Parisi S, Azzani P, Bonanni P, Castiglia P, Conversano M, Icardi G, Tognetto A, Checucci Lisi G. Invasive meningococcal diseases in Italy: an analysis of national surveillance data, 2011–2017. 2019. https://epidemioint. wp-content/uploads/sites/21/2019/05/ESPID-2019-Accepted-Abstracts-Listed.pdf. Accesssed 24 Mar 2021. In: vol. 2021; 2019.

50. Stoof SP, Rodenburg GD, Knol MJ, Rumke LW, Bovenklerk S, Berbers GAM, Spanjaard L, van der Ende A, Sanders EAM. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281–92.

51. Loonenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015–2018. Clin Infect Dis. 2020;70(10):2036–44.

52. Eriksson L, Hedberg ST, Jacobsson S, Fredlund H, Mölling P, Stenmark B. Whole-genome sequencing of emerging invasive Neisseria meningitidis serogroup W in Sweden. J Clin Microbiol. 2018;56(4):e01409-01417.

53. Bennett D, O’Lorcain P, Morgan S, Cotter S, Cafferkey M, Cunney R. Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. Epidemiol Infect. 2019;147:e142.

54. Bjilma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, van der Ende A, van De Beek D. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis. 2016;16(3):339–47.

55. Clarke C, Mallonee S. State-based surveillance to determine trends in Peruski AH, Kludt P, Patel RS, DeMaria A. Secular trends in invasive meningococcal disease in Italy: an analysis of national surveillance data, 2011–2017. 2019. https://espid meeting. org/wp‑content/uploads/sites/21/2019/05/ESPID‑2019‑Accepted‑Abstracts‑Listed. pdf. Accesssed 24 Mar 2021. In: vol. 2021; 2016.

56. Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of Neisseria meningitidis sepsis in a patient with acute epiglottitis and respiratory failure. BMJ Case Rep. 2018;2018:bcr2017223388.

57. Cikirikcioglu M, Schrenzel J, Emonet S, Muller H, Ellenberger C, Giraud R, Kaiser L, Huber C. Keep in mind extremely rare etiologies!!! Meningococcal aortic valve endocarditis. Kardiovaskulare Medizin. 2017;20(5):S123.

58. Romero-Gomez MP, Rentero Z, Paño JR, Mingorance J. Bacteremia pneumonia caused by Neisseria meningitidis serogroup Y. Respir Med Case Rep. 2012;8(1):23–4.

59. Singh D, Swann A. Skin demarcation and amputation level for foot gangrene following meningococcal septicaemia. Foot Ankle Spec. 2013;6(5):384–8.

60. Arnáiz-García ME, Arnáiz-García AM, Gutierrez-Diez F, Nistal JF, González-Santos JM, Pulitani I, Amado-Diago C, Arnáiz J. Mutilating purpurea fulminans in an adult with meningococcal sepsis. P R Health Sci J. 2017;36(3):179–82.

61. Zimmerman T, Chimie C. Neisseria meningitidis sepsis in a patient with acute epiglottitis and respiratory failure. BMJ Case Rep. 2018;2018:bcr2017223388.

62. Lawler J, Lucidarme J, Parikh S, Smith L, Campbell H, Borrow R, Gray S, Foster K, Ladhan S. Suspected cluster of Neisseria meningitidis W135 type 2a in a healthcare event of Neisseria meningitidis serogroup W (MenW) clonal complex 11, the Netherlands, March 2017. Euro Surveill. 2017;22(23):30549.

63. Puleston R, Beck C, Tahir M, Bardhan M, Charlemagne P, Alves C, Ladhan S, Watson C, Ramsay M, Kazcmarki E, et al. An unusual transmission of Neisseria meningitidis W invasive disease in an elderly care home: do new laboratory methods aid public health action? United Kingdom, 2015. Euro Surveill. 2019;24(23):1900070.

64. Beebeejaun K, Parikh SR, Campbell H, Gray S, Borrow R, Ramsay ME, Ladhan S. Invasive meningococcal disease: timing and cause of death in England, 2008–2015. J Infect. 2020;80(5):286–90.

65. Ristic M, Seguljev Z, Petrovic V, Rajcevic S. Epidemiological characterizations of meningococcal disease in Vojvodina (Serbia) at the beginning of 21st Century. HealthMED. 2012;6(7):2550–4.

66. Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T, Antoniazzi S, Pozzi M, Radice S, Clementi E. Epidemiological analysis on two decades of hospitalisations for meningitis in the United States. Eur J Clin Microbiol Infect Dis. 2014;33(9):1519–24.

83. Meningitis progress tracker [https://www.meningitis.org/mpt]
84. Disease data from ECDC surveillance atlas for meningococcal disease [https://ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas].
85. Polkowska A, Toropainen M, Ollgren J, Lyytkäinen O, Nuortti JP. Bacterial meningitis in Finland, 1995–2014: a population-based observational study. BMJ Open. 2017;7(5):e015080.
86. Meningococcal disease [https://www.cdc.gov/ meningococcal/disease/index.html].
87. Rapport d’activité 2014 [https://www.pasteur.fr/fr/file/3273/download?token=8u8anuHx0].
88. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2018 [https://www.cdc.gov/abcs/reports-findings/surveysengeance18.html].
89. Bodilsen J, Brandt CT, Sharew A, Dalager-Pedersen M, Benfield T, Schønheyder HC, Nielsen H. Early versus late diagnosis in community-acquired bacterial meningitis: a retrospective cohort study. Clin Microbiol Infect. 2018;24(2):166–70.
90. Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82.
91. Reese HE, Ronveaux O, Mwenda JM, Bita A, Cohen AL, Novak RT, Fox LM, Soeters HM. Invasive meningococcal disease in Africa’s meningitis belt: more than just meningitis? J Infect Dis. 2019;220(220 Suppl 4):S263–5.
92. Taha MK, Presa J, Serra L. A review of the epidemiology of invasive meningococcal disease and vaccination strategies in North Africa. Int J Infect Dis. 2020;104:189–97.
93. Lahra MM, Enriquez RP, George CRR. Australian meningococcal surveillance programme annual report, 2017. Commun Dis Intell. 2018;42:2017.
94. Fukusumi M, Kamiya H, Takahashi H, Kanai M, Hachisu Y, Saitoh T, Ohnishi M, Oishi K, Sunagawa T. National surveillance for meningococcal disease in Japan, 1999–2014. Vaccine. 2016;34(34):4068–71.
95. Muscat M, Spiteri G, Cachia A, Halden J, Gray SJ, Melillo JM, Mamo J, Cuschieri P. Invasive meningococcal disease in Malta: an epidemiological overview, 1994–2007. J Med Microbiol. 2009;58(Pt 11):e15493.
96. Brueggemann AB, van Jansen-Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MJC, van der Linden MP, Amin-Chowdhury Z, Bennett DE, Borowiak R, et al. Changes in the incidence of invasive disease due to streptococcus pneumoniae, haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the invasive respiratory infection surveillance initiative: a prospective analysis of surveillance data. Lancet Digital Health. 2021;3(6):e360–70.
97. Tuite AR, Kinlin LM, Jolley KA, Whalley MJ, Wang X, Cohn AC, MacNeil JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009–2013. Clin Infect Dis. 2019;68(4):580–5.
98. Calendario vaccinale per la vita 2019 [https://www.vaccinarsi.org/notizie/2019/07/NE2%80%8Bcalendario-vaccinale-per-la-vita-2019].

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions